Reserve your spot today for the Satellite Breakfast Symposium Managed Care Review BoardTM - Examining Novel Therapies and Quality Improvement Initiatives for the Treatment of Heart Failure

Jointly provided by     This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation. Tuesday, October 4, 2016 6:00 AM - 7:45 AM Gaylord National Hotel & Convention Center Room: Maryland D National Harbor, MD Held in conjunction with AMCP Nexus 2016 Please note: No additional fee is required to attend this CME/CPE activity; however, registration to AMCP Nexus 2016 is required.

Click here to download the slides from this symposium.

HOT TOPICS

Clinical benefits of therapeutic decision-making in a new era of novel therapies Integration of quality of care measures with plan-wide initiatives to improve outcomes and manage costs Health economic and pharmacoeconomic assessment of emerging treatment options Care coordination and member benefit strategies to enhance patient outcomes

DISTINGUISHED FACULTY PRESENTERS

Jeffrey Borer, MD Professor of Medicine, Cell Biology, Radiology, and Surgery Chief, Division of Cardiovascular Medicine SUNY Downstate Medical Center Adjunct Professor and Attending Physician, Cardiothoracic Surgery Weill Medical College of Cornell University Jeffrey Dunn, PharmD, MBA Senior Vice President Chief Clinical Officer VRx Pharmacy Services, LLC John Fox, MD, MHA Senior Medical Director Associate Vice President, Medical Affairs Priority Health Fadia Tohme-Shaya, PhD, MPH Professor Vice Chair for Academic Affairs PHSR University of Maryland School of Pharmacy

WHO SHOULD ATTEND?

This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of AMCP, and other managed health care professionals attending AMCP Nexus 2016.

STATEMENT OF NEED / PROGRAM OVERVIEW

Annually, >1 million patients are hospitalized with a primary diagnosis of heart failure (HF), and HF is the leading cause of hospitalization among adults >65 years of age in the United States. This HF-associated hospitalization represents a noteworthy driver of health care-related costs for managed care stakeholders, and serves as a surrogate marker for increasing mortality. Rehospitalization, despite dramatic improvement in outcomes with medical therapy, is also not uncommon: at least half of patients are readmitted to hospital within 6 months of discharge. This exemplifies a key area of interest for payers across all disease states, since reducing readmission rates also reduces costs and indicates an improvement in the quality of care. The Managed Care Review BoardTM format features multi-specialty, multi-professional managed care, and clinical specialist faculty who collaborate on the review of the clinical data, current guidelines, and economic data of a specific class of therapeutics. It uniquely provides the audience with a review of important, relevant therapeutic category information and features peer-to-peer exchange between a diverse group of managed care and clinical specialist faculty contributors. This symposium is designed to engage the faculty and audience to develop solutions for managed care professionals to implement within their own setting to improve outcomes for patients with HF. This approach supports managed care pharmacists by enhancing the results of their own health care organization's systematic literature reviews and analyses.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to demonstrate improved ability to: Describe the available efficacy and safety data for emerging therapies in heart failure (HF), including results from pivotal trials and evidence supporting averted HF-related hospitalizations and/or deaths Apply appropriate positioning and utilization management criteria to facilitate judicious and effective utilization of emerging therapies for HF Discuss available HF quality measures from nationally recognized governing bodies as well as from other health plans across the nation Illustrate opportunities for HF quality improvement in health plan operations and infrastructure and implement measures to facilitate evidence-based prescribing and follow-up Characterize the importance of addressing noncardiac comorbidities and overseeing care transitions as they pertain to maintaining therapeutic persistence and improving outcomes Develop collaborative strategies for HF management enlisting the input and support of a multidisciplinary team of health care providers

AGENDA

Date and Time Tuesday, October 4, 2016 6:00 AM - 7:45 AM Gaylord National Hotel & Convention Center Room: Maryland D National Harbor, MD

6:00 AM Opening Comments and Pre-activity Assessment 6:05 AM Assessing the Clinical Benefits of Therapeutic Decision-Making in a New Era of Heart Failure Therapies Jeffrey Borer, MD 6:30 AM Integration of Quality of Care Measures with Plan-Wide Initiatives to Improve Outcomes and Manage Costs John Fox, MD, MHA 6:50 AM Faculty Idea Exchange Faculty Panel 6:55 AM Health Economic and Pharmacoeconomic Assessment: Optimizing the Overall Value of Emerging Treatment Options Fadia Tohme-Shaya, PhD, MPH 7:15 AM Care Coordination and Member Benefit Strategies to Enhance Patient Outcomes Across the Continuum of Heart Failure Management Jeffrey Dunn, PharmD, MBA 7:35 AM Moderated Faculty Panel Discussion and Audience Q&A Closing Comments Post-activity Assessment and Evaluations 7:45 AM Adjournment

ACCREDITATION INFORMATION

Physician Continuing Medical Education Accreditation Statement This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Medical Education Resources designates this live activity for a maximum of 1.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Pharmacist Continuing Education Accreditation Statement

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation MER designates this continuing education activity for 1.75 contact hours (0.175 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0816-9999-16-076-L01-P Type of Activity: Knowledge

Disclosure of Conflicts of Interest It is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Americans with Disabilities Act Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Impact Education, LLC, prior to the live event at (215) 619-8812. Fee Information Please note: No additional fee is required to attend this CPE/CME activity; however, registration to AMCP Nexus 2016 is required. Pre-registration will close at 12:00 pm on October 3, 2016. Walk-in registration will be available at the time of the program. If you have any questions, please call (215) 619-8812 or email info@impactedu.net.